Literature DB >> 21962758

Leflunomide in dermatology.

Alan S Boyd1.   

Abstract

Leflunomide is an oral disease-modifying antirheumatic drug administered to patients with rheumatoid and psoriatic arthritis. This drug inhibits dihydroorotate dehydrogenase, an enzyme critical in the production of intracellular pyrimidines, and down-regulates tumor necrosis factor-alfa activity. Leflunomide has demonstrated usefulness in treating cutaneous psoriasis along with other dermatologic and rheumatologic conditions.
Copyright © 2011 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21962758     DOI： 10.1016/j.jaad.2011.08.025

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN： 0190-9622            Impact factor:   11.527


  3 in total

1.  Original 2-(3-Alkoxy-1H-pyrazol-1-yl)azines Inhibitors of Human Dihydroorotate Dehydrogenase (DHODH).

Authors:  Marianne Lucas-Hourani; Hélène Munier-Lehmann; Farah El Mazouni; Nicholas A Malmquist; Jane Harpon; Eloi P Coutant; Sandrine Guillou; Olivier Helynck; Anne Noel; Artur Scherf; Margaret A Phillips; Frédéric Tangy; Pierre-Olivier Vidalain; Yves L Janin
Journal:  J Med Chem       Date:  2015-06-30       Impact factor: 7.446

Review 2.  Epigenetic Regulation of Ferroptosis-Associated Genes and Its Implication in Cancer Therapy.

Authors:  Yanzi Pei; Yujie Qian; Hao Wang; Li Tan
Journal:  Front Oncol       Date:  2022-01-31       Impact factor: 6.244

3.  Leflunomide Sustained Skin Delivery Based on Sulfobetaine-Modified Chitosan Nanoparticles Embedded in Biodegradable Polyesters Films.

Authors:  Stavroula G Nanaki; Evi Christodoulou; Nikolaos D Bikiaris; Afroditi Kapourani; Konstantinos N Kontogiannopoulos; Souzan Vergkizi-Nikolakaki; Panagiotis Barmpalexis
Journal:  Polymers (Basel)       Date:  2021-03-21       Impact factor: 4.329
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.